References
- Huttunen KM, Raunio H, Rautio J. Prodrugs–from serendipity to rational design. Pharmacol Rev. 2011;63:750–771.
- Rautio J, Kumpulainen H, Heimbach T, et al. Prodrugs: design and clinical applications. Nat Rev Drug Discov. 2008;7:255–270.
- Hsieh P, Hung C, Fang J. Current prodrug design for drug discovery. Curr Pharm Des. 2009;15:2236–2250.
- Ettmayer P, Amidor GL, Clement B, et al. Lessons learned from marketed and investigational prodrugs. Med Chem. 2004;47:2393–2404.
- Stella V, Charman WNA, Naringrekar V. Prodrugs: do they have advantages in clinical practice? Drugs. 1985;29:455–473.
- Rautio J. Prodrug strategies in drug design Rautio J. In: Rautio J, editor. Prodrugs and targeted delivery: towards better ADME properties. Weinheim: Wiley-VCH Verlag GmbH & Co. KGaA; 2010. p. 1–30.
- Bey P. “Pro-drugs” activees specifiquement par le recepteurcible: inhibition enzymatic du type kcat. Sci Tech Pharm. 1978;7:171–176.
- Stella V, Nti-Addae KO. Prodrugs: challenges and rewards part 1 & 2. New York, NY: Springer Science + Business Media; 2007.
- He G, Massarella J, Ward P. Clinical pharmacokinetics of the prodrug oseltamivir and its active metabolite Ro 64-0802. Clin Pharmacokinet. 1999;37:471–484.
- Stella V, Nti-Addae K. Prodrug strategies to overcome poor water solubility. Adv Drug Deliv Rev. 2007;59:677–694.
- Chakravarthi K, Vijayaraj S, Venugopal A, et al. Role of prodrugs in solubility enhancement of drugs. PharmaTutor Mag. 2014;2:33–48.
- Glazko AJ, Edgerton WH, Dill WA, et al. Chloromycetin palmitate: a synthetic ester of chloromycetin. Antibiot Chemother. 1952;2:234–242.
- Glaxo SmithKline. Lexiva prescribing information. NC: Research Triangle Park; 2015.
- Ariens EJ, Simonis AM. Drug action: target tissue, dose response relationships and receptors. In: Teorell T, editor. Pharmacology and pharmacokinetics. New York (NY): Plenum Press; 1974. p. 163–189.
- Schwartz M, Hayton W. Relative stability of hetacillin and ampicillin in solution. J Pharm Sci. 1972;61:906–909.
- Davies GE, Driver GW. The antitubercullous activity of ethyl thiolesters with particular reference to diethyl dithiolisophthalate. Br J Pharmacol Chemother. 1957;12:434–437.
- Boucher B. Fosphenytoin: a novel phenytoin prodrug. Pharmacotherapy. 1996;16:777–791.
- Pandeya SN, Dimmock JR. An introduction to drug design. New Dehli: New Age International Limited; 1997.
- Horter D, Dressman J. Influence of physicochemical properties on dissolution of drugs in the gastrointestinal tract. Adv Drug Deliv Rev. 2001;46:75–87.
- Karim A, Laurent A, Slater ME, et al. A pharmacokinetic study of intramuscular (i.m.) parecoxib sodium in normal subjects. J Clin Pharmacol. 2001;41:1111–1119.
- XenoPort, Inc. Horizant prescribing information. Santa Clara (CA): XenoPort, Inc.; 2013.
- Kreienbaum M. Stability of betamethasone sodium phosphate, hydrocortisone sodium phosphate, and prednisolone sodium phosphate injections submitted by U.S. hospitals. Am J Hosp Pharm. 1986;43:1747–1750.
- Enalapril. 2015; Available from: http://pubchem.ncbi.nlm.nih.gov/compound/enalapril#section=Top
- Cassidy TA, McNaughton EC, Varughese S, et al. Nonmedical use of prescription ADHD stimulant medications among adults in a substance abuse treatment population: early findings from the NAVIPPRO surveillance system. J Atten Disord. 2013;19:275–283.
- Cassidy TA, Varughese S, Russo L, et al. Nonmedical use and diversion of ADHD stimulants among U.S. adults ages 18-49: a national internet survey. J Atten Disord. 2012;19:630–640.
- Sweeney CT, Sembower MA, Ertischek MD, et al. Nonmedical use of prescription ADHD stimulants and preexisting patterns of drug abuse. J Addict Dis. 2013;32:1–10.
- Vyvanse. C17H33N3O7S2 - PubChem.pdf. 2015; [ cited 2015 Nov 1]. Available from: http://pubchem.ncbi.nlm.nih.gov/compound/Vyvanse#section=Top
- Katz N. Abuse-deterrent opioid formulations: are they a pipe dream? Curr Rheumatol Rep. 2008;10:11–18.
- Schaeffer T. Abuse-deterrent formulations, an evolving technology against the abuse and misuse of opioid analgesics. J Med Toxicol. 2012;8:400–407.
- Volkow ND America’s addition to Opioids: Heroin and prescription drug abuse. 2014. National Institute of Drug Abuse; [ cited 2015 Oct 31]. Available from: http://www.drugabuse.gov/about-nida/legislative-activities/testimony-to-congress/2014/americas-addiction-to-opioids-heroin-prescription-drug-abuse#_ftn4
- CDC. Vital signs: overdoses of prescription opioid pain relievers - United States, 1999-2008. Morb Mortal Wkly Rep. 2011;60:1487–1492.
- World Drug Report. United Nations Office on Drugs and Crime; 2012. Available from: https://www.unodc.org/documents/data-and-analysis/WDR2012/WDR_2012_web_small.pdf
- Shei A, Hirst M, Kirson NY, et al. Estimating the health care burden of prescription opioid abuse in five European countries. ClinicoEcon and Outcomes Res. 2015;7:477–488.
- CDC. Prescription drug overdose data: Deaths from prescription opioid overdose. 2015
- Strassels SA. Economic burden of prescription opioid misuse and abuse. J Manag Care Pharmacy. 2009;15:556–562.
- Birnbaum HG, White AF, Schiller M, et al. Societal costs of prescription opioid abuse, dependence, and misuse in the United States. Pain Medicine. 2011;12:657–667.
- Bates C, Laciak R, Southwick A, et al. Overprescription of postoperative narcotics: a look at postoperative pain medication deliver, consumption and disposal in urological practice. J Urol. 2011;185:551–555.
- Results from the 2011 National Survey on Drug Use and Health: Summary of National Findings, NSDUH Series H-44, HHS Publication No. (SMA) 12-4713. 2012; [ cited 2015 Oct 31]. Substance Abuse and Mental Health Services Administration,: Available at: http://www.samhsa.gov/data/sites/default/files/NSDUHresultsPDFWHTML2013/Web/NSDUHresults2013.pdf
- Cicero TJ, Ellis MS, Harney J. Shifting patterns of prescription opioid and heroin abuse in the United States. N Engl J Med. 2015;373(18):1789–1790.
- Fudin J Abuse-deterrent opioid formulations: purpose, practicality, and paradigms. Pharmacy Times 2015; January 27, 2015: Available from: http://www.pharmacytimes.com/contributor/jeffrey-fudin/2015/01/abuse-deterrent-opioid-formulations-purpose-practicality-and-paradigms
- Food and Drug Administration Safety and Innovation Act (FDASIA), Public Law 112-114. 2012.
- Abuse-deterrent opioids – Evaluation and labeling: guidance for Industry. HHS FDA; 2015; [ cited 2015 Oct 31]. Available from: http://www.fda.gov/downloads/drugs/guidancecomplianceregulatoryinformation/guidances/ucm334743.pdf
- Setlik J, Bond GR, Ho M. Adolescent prescription ADHD medication abuse is rising along with prescriptions for these medications. Pediatrics. 2009;124:875–880.
- Vyvanse Prescribing Information. Wayne (PA): Shire US Inc; 2015.
- Jasinski DR, Krishnan S. Human pharmacology of intravenous lisdexamfetamine dimesylate: abuse liability in adult stimulant abusers. J Psychopharmacol. 2009;23:410–418.
- Jasinski DR, Krishnan S. Abuse liability and safety of oral lisdexamfetamine dimesylate in individuals with a history of stimulant abuse. J Psychopharmacol. 2009;23:419–427.
- Morphine in DrugBank Version 4.1. 2013; [ cited 2015 Oct 31]. Available from: http://www.drugbank.ca/drugs/DB000295
- Oral opioid dosing equivalents and conversions. U. Michigan; 2009; [ cited 2015 Oct 31]. Available from: http://www.med.umich.edu/1info/FHP/practiceguides/pain/dosing.pdf
- Hydrocodone. Drug Enforcement Administration; 2014; [ cited 2015 Oct 31]. Available from: http://www.deadiversion.usdoj.gov/drug_chem_info/hydrocodone.pdf
- Hydrocodone. DrugBank; 2013; [ cited 2015 Oct 31]. Available from: http://www.drugbank.ca/drugs/db00956
- Navani DM, Yoburn BC. In vivo activity of norhydrocodone: an active metabolite of hydrocodone. J Pharmacol Exp Ther. 2013;347:497–505.
- DEA Final Rule Rescheduling Hydrocodone Combination Products. American Medical Association; 2014.
- Schedules of Controlled Substances: rescheduling of Hydrocodone Combination Products From Schedule III to Schedule II. Office of the Federal Register; 2014; [ cited 2015 Oct 31]. Available from: https://www.federalregister.gov/articles/2014/08/22/2014-19922/schedules-of-controlled-substances-rescheduling-of-hydrocodone-combination-products-from-schedule
- Young AM, Havens JR, Leukefeld CG. Route of administration for illicit prescription opioids: a comparison of rural and urban drug users. Harm Reduct J. 2010;7:24.
- KemPharm, Inc. Completes human abuse liability program for KP201/APAP. Globe Newswire: KemPharm, Inc; 2015. Press release; [ cited 2015 Oct 29]. Available from: http://investors.kempharm.com/phoenix.zhtml?c=253970&p=irol-newsArticle&ID=2099179
- KemPharm’s KP201 Demonstrates Complete Metabolic Cleavage of Prodrug and Steady-State Pharmacokinetic Profiles for Hydrocodone, Hydromorphone and Acetaminophen. KemPharm, Inc; 2013. News release. Aug 26; [ cited 2015 Oct 30]. Available from: http://investors.kempharm.com/phoenix.zhtml?c=253970&p=irol-newsArticle_print&ID=2030673
- KemPharm, Inc. Announces Positive Data From Intranasal Human Abuse Liability Study of KP201/APAP. KemPharm, Inc; 2015. Press Release. Available from: [ cited 2015 Oct 30]. http://investors.kempharm.com/phoenix.zhtml?c=253970&p=irol-newsArticle_print&ID=2079573
- KemPharm, Inc. Reports Positive Data From Oral Human Abuse Liability Clinical Trial of KP201/APAP. KemPharm, Inc.; 2015: Press Release; [ cited 2015 Oct 30]. Available from: http://investors.kempharm.com/phoenix.zhtml?c=253970&p=irol-newsArticle_print&ID=2058473
- KemPharm Reports Positive Data Demonstrating Tamper-Resistant Properties of KP201/APAP Results Indicate That Prodrug Design of KP201/APAP Significantly Hinders Traditional Means of Abuse, Including Extraction, Injection and Smoking. KemPharm, Inc; 2015: Press Release; [ cited 2015 Oct 30]. Available from: http://investors.kempharm.com/phoenix.zhtml?c=253970&p=irol-newsArticle_print&ID=2091720
- KemPharm’s KP201 Demonstrates Bioequivalence Compared to Norco® in Key Pivotal Clinical Study. KemPharm, Inc; 2013; [ cited 2015 Oct 30]. Press Release. Available at: http://investors.kempharm.com/phoenix.zhtml?c=253970&p=irol-newsArticle&ID=2030658
- KemPharm, Inc. Abuse-Deterrent Prodrug Pipeline for Pain. KemPharm, Inc; 2015; [ cited 2015 November 1]. Available from: http://www.kempharm.com/pages/pipeline/pain.php
- Signature Therapeutics Website. BIO-MD™ Opioids: abuse-resistant Opioid Prodrugs. 2015; [ cited 2011 Jan 31]. Available from: http://www.signaturerx.com/view.cfm/59/Abuse-Resistant-Opioids